Glenmark Pharmaceuticals has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.
Further, Glenmark has announced a price reduction of 27% for FabiFlu. The new MRP is Rs 75 per tab from the earlier Rs 103 per tab. The price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country. Glenmark’s price reduction aims to make FabiFlu further accessible for COVID-19 patients across the country.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
